Release
📈 Stocks
Alebund Pharmaceuticals Unveils Phase IIb Trial Design for AP306 Candidate
(53 minutes ago)
Alebund Pharmaceuticals and partner R1 Therapeutics have detailed the Phase IIb trial design for AP306, marking a key procedural milestone in the…